Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions.

Jones B, Koch AE, Ahmed S.

Front Immunol. 2012 Jan 2;2:82. doi: 10.3389/fimmu.2011.00082. eCollection 2011.

2.

The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion.

Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A.

Blood. 2003 Aug 15;102(4):1186-95. Epub 2003 Apr 24.

3.

CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver.

Bourd-Boittin K, Basset L, Bonnier D, L'helgoualc'h A, Samson M, Théret N.

J Cell Mol Med. 2009 Aug;13(8A):1526-35. doi: 10.1111/j.1582-4934.2009.00787.x. Epub 2009 May 11.

4.

Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1).

Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW.

J Biol Chem. 2001 Oct 12;276(41):37993-8001. Epub 2001 Aug 8.

5.

Fractalkine in rheumatoid arthritis and allied conditions.

Umehara H, Tanaka M, Sawaki T, Jin ZX, Huang CR, Dong L, Kawanami T, Karasawa H, Masaki Y, Fukushima T, Hirose Y, Okazaki T.

Mod Rheumatol. 2006;16(3):124-30. Review.

PMID:
16767549
6.

Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential.

D'Haese JG, Demir IE, Friess H, Ceyhan GO.

Expert Opin Ther Targets. 2010 Feb;14(2):207-19. doi: 10.1517/14728220903540265. Review.

PMID:
20055718
7.

Fractalkine/CX3CL1 enhances GABA synaptic activity at serotonin neurons in the rat dorsal raphe nucleus.

Heinisch S, Kirby LG.

Neuroscience. 2009 Dec 15;164(3):1210-23. doi: 10.1016/j.neuroscience.2009.08.075. Epub 2009 Sep 10. Erratum in: Neuroscience. 2010 Feb 17;165(4):1559-60.

8.

Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis.

Blaschke S, Koziolek M, Schwarz A, Benöhr P, Middel P, Schwarz G, Hummel KM, Müller GA.

J Rheumatol. 2003 Sep;30(9):1918-27.

PMID:
12966591
9.

Modulation of platelet and monocyte function by the chemokine fractalkine (CX3 CL1) in cardiovascular disease.

Flierl U, Bauersachs J, Schäfer A.

Eur J Clin Invest. 2015 Jun;45(6):624-33. doi: 10.1111/eci.12443. Epub 2015 Apr 24. Review.

PMID:
25832902
10.

[Fractalkine and inflammatory diseases].

Imai T, Nishimura M, Nanki T, Umehara H.

Nihon Rinsho Meneki Gakkai Kaishi. 2005 Jun;28(3):131-9. Review. Japanese.

11.

Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons.

Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O.

J Biol Chem. 2010 Apr 2;285(14):10563-71. doi: 10.1074/jbc.M109.035477. Epub 2010 Feb 2.

12.

Altered fractalkine cleavage results in an organ-specific 17 kDa fractalkine fragment in salivary glands of NOD mice.

Delaleu N, Jonsson R.

Arthritis Res Ther. 2008;10(4):114. doi: 10.1186/ar2458. Epub 2008 Jul 31.

13.

Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.

Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM, Leesnitzer MA, Becherer JD.

Comb Chem High Throughput Screen. 2005 Mar;8(2):161-71. Review.

PMID:
15777180
14.

Fractalkine in vascular biology: from basic research to clinical disease.

Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T.

Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):34-40. Epub 2003 Sep 11. Review.

15.

Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.

Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von Hundelshausen P, Winter U, Paliga K, Reiss K, Saftig P, Weber C, Ludwig A.

J Immunol. 2007 Jun 15;178(12):8064-72.

16.

Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update.

D'Haese JG, Friess H, Ceyhan GO.

Expert Opin Ther Targets. 2012 Jun;16(6):613-8. doi: 10.1517/14728222.2012.682574. Epub 2012 Apr 25. Review.

PMID:
22530606
17.

Altered fractalkine cleavage potentially promotes local inflammation in NOD salivary gland.

Wildenberg ME, van Helden-Meeuwsen CG, Drexhage HA, Versnel MA.

Arthritis Res Ther. 2008;10(3):R69. doi: 10.1186/ar2441. Epub 2008 Jun 19.

18.

Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators.

White GE, Greaves DR.

Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):589-94. doi: 10.1161/ATVBAHA.111.237412. Epub 2012 Jan 12. Review.

19.

Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption.

Koizumi K, Saitoh Y, Minami T, Takeno N, Tsuneyama K, Miyahara T, Nakayama T, Sakurai H, Takano Y, Nishimura M, Imai T, Yoshie O, Saiki I.

J Immunol. 2009 Dec 15;183(12):7825-31. doi: 10.4049/jimmunol.0803627.

20.

Chemokines in rheumatic diseases.

Szekanecz Z, Szücs G, Szántó S, Koch AE.

Curr Drug Targets. 2006 Jan;7(1):91-102. Review.

PMID:
16454702

Supplemental Content

Support Center